Celemics is a biomaterial technology company that uses DNA-based biomaterials and revolutionary sequencing technology to lead the way for the medical, pharmaceutical, microbiome, synthetic biology, and breeding fields. Through its practical implementation into the aforementioned areas and various other biological R&D fields, Celemics hopes to rapidly advance the innovations made in medical and scientific technology and contribute to the safety and health of all. (www.celemics.com)
Celemics is a biomaterial technology company that uses DNA-based biomaterials and revolutionary sequencing technology to lead the way for the medical, pharmaceutical, microbiome, synthetic biology, and breeding fields. Through its practical implementation into the aforementioned areas and various other biological R&D fields, Celemics hopes to rapidly advance the innovations made in medical and scientific technology and contribute to the safety and health of all. (www.celemics.com)
![[Webinar] Cancer Variant Prioritization and Reporting using StrandOmics thumbnail](https://www.celemics.com/wp-content/uploads/2023/05/webinar-cancer-variant-prioritization-and-reporting-using-strandomics-min.jpg)
[Celemics X Strand Life Sciences Webinar] Celemics and Strand Life Sciences recently announced their partnership to develop a bioinformatics solution that integrates the Celemics bioinformatics pipeline into the StrandOmics environment to enable fast tertiary analysis and reporting of variants from solid tumor genetic tests. The cloud-based, HIPAA-compliant StrandOmics platform relies on a knowledge-base for interpretation of solid tumor and heme variants with over 500 genes, 20,000 variants, 110 FDA drugs and 80,000 clinical trials. StrandOmics has been used to generate clinical reports on ≈10,000 clinical samples tested at Strand’s CAP-accredited genomics lab. It is also used to interpret and report on sequenced data from solid tumor testing for clients in the US and APAC regions. In this webinar our speakers, Dr Urvashi Bahadur and Ernie Kim, will showcase the StrandOmics platform for the interpretation and clinical reporting of solid tumor variants, and additionally discuss the Celemics 405-gene pan cancer solid tumor panel.
Celemics is a biomaterial technology company that uses DNA-based biomaterials and revolutionary sequencing technology to lead the way for the medical, pharmaceutical, microbiome, synthetic biology, and breeding fields. Through its practical implementation into the aforementioned areas and various other biological R&D fields, Celemics hopes to rapidly advance the innovations made in medical and scientific technology and contribute to the safety and health of all. (www.celemics.com)
[Celemics X Strand Life Sciences Webinar] Celemics and Strand Life Sciences recently announced their partnership to develop a bioinformatics solution that integrates the Celemics bioinformatics pipeline into the StrandOmics environment to enable fast tertiary analysis and reporting of variants from solid tumor genetic tests. The cloud-based, HIPAA-compliant StrandOmics platform relies on a knowledge-base for interpretation of solid tumor and heme variants with over 500 genes, 20,000 variants, 110 FDA drugs and 80,000 clinical trials. StrandOmics has been used to generate clinical reports on ≈10,000 clinical samples tested at Strand’s CAP-accredited genomics lab. It is also used to interpret and report on sequenced data from solid tumor testing for clients in the US and APAC regions. In this webinar our speakers, Dr Urvashi Bahadur and Ernie Kim, will showcase the StrandOmics platform for the interpretation and clinical reporting of solid tumor variants, and additionally discuss the Celemics 405-gene pan cancer solid tumor panel.
Celemics is a biomaterial technology company that uses DNA-based biomaterials and revolutionary sequencing technology to lead the way for the medical, pharmaceutical, microbiome, synthetic biology, and breeding fields. Through its practical implementation into the aforementioned areas and various other biological R&D fields, Celemics hopes to rapidly advance the innovations made in medical and scientific technology and contribute to the safety and health of all. (www.celemics.com)
[Celemics X Strand Life Sciences Webinar] Celemics and Strand Life Sciences recently announced their partnership to develop a bioinformatics solution that integrates the Celemics bioinformatics pipeline into the StrandOmics environment to enable fast tertiary analysis and reporting of variants from solid tumor genetic tests. The cloud-based, HIPAA-compliant StrandOmics platform relies on a knowledge-base for interpretation of solid tumor and heme variants with over 500 genes, 20,000 variants, 110 FDA drugs and 80,000 clinical trials. StrandOmics has been used to generate clinical reports on ≈10,000 clinical samples tested at Strand’s CAP-accredited genomics lab. It is also used to interpret and report on sequenced data from solid tumor testing for clients in the US and APAC regions. In this webinar our speakers, Dr Urvashi Bahadur and Ernie Kim, will showcase the StrandOmics platform for the interpretation and clinical reporting of solid tumor variants, and additionally discuss the Celemics 405-gene pan cancer solid tumor panel.
Celemics is a biomaterial technology company that uses DNA-based biomaterials and revolutionary sequencing technology to lead the way for the medical, pharmaceutical, microbiome, synthetic biology, and breeding fields. Through its practical implementation into the aforementioned areas and various other biological R&D fields, Celemics hopes to rapidly advance the innovations made in medical and scientific technology and contribute to the safety and health of all. (www.celemics.com)
[Celemics X Strand Life Sciences Webinar] Celemics and Strand Life Sciences recently announced their partnership to develop a bioinformatics solution that integrates the Celemics bioinformatics pipeline into the StrandOmics environment to enable fast tertiary analysis and reporting of variants from solid tumor genetic tests. The cloud-based, HIPAA-compliant StrandOmics platform relies on a knowledge-base for interpretation of solid tumor and heme variants with over 500 genes, 20,000 variants, 110 FDA drugs and 80,000 clinical trials. StrandOmics has been used to generate clinical reports on ≈10,000 clinical samples tested at Strand’s CAP-accredited genomics lab. It is also used to interpret and report on sequenced data from solid tumor testing for clients in the US and APAC regions. In this webinar our speakers, Dr Urvashi Bahadur and Ernie Kim, will showcase the StrandOmics platform for the interpretation and clinical reporting of solid tumor variants, and additionally discuss the Celemics 405-gene pan cancer solid tumor panel.